Global pharmaceutical companies are ramping up pressure on European governments over healthcare spending controls. Germany has become the latest focal point of intense industry resistance. Drugmakers facing tighter financial regulations across Europe are deploying a familiar strategy. They are warning policymakers that local investments, facility expansions, and patient access to life-saving medicines are at risk. This playbook recently delivered major…
Tag: Market Access
-
German Drug Price Reforms Shake Pharma And Hospitals
Germany’s cost-of-care debate is moving from rhetoric to legislation. And it is landing hard on medicines and hospitals. The latest discussions on German drug price reforms come as Berlin is trying to stabilise statutory health insurance funds that are projected to drift deeper into deficit. Government estimates put the potential shortfall at around €40bn by 2030 if spending is not…
-
Oral Phenylephrine Phase-Out Puts OTC Brands Under Review
South Africa’s medicines regulator is under mounting pressure from pharmaceutical manufacturers. This comes after it signalled it may phase out oral phenylephrine in over-the-counter (OTC) cold and flu medicines. The South African Health Products Regulatory Authority (SAHPRA) says the concern is simple: the ingredient may not work as a nasal decongestant when taken by mouth. Phenylephrine still appears in long-standing…